Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Localised prostate cancer, very low and low risk, drawn from the whole corpus: 6 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Which Grade Group 1 cancers will upgrade, and whether Grade Group 1 should be called cancer at all.
How often to repeat biopsy on surveillance and whether MRI alone can replace it.
Overdiagnosis by PSA screening against the deaths screening prevents.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
5-year biochemical or clinical failure-free 95.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Clinically significant cancer 38% vs 26%.
A milestone in how this cancer is treated.